Human melanocytes do not express EGF receptors.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed, 16 citations in OpenAlex.

1. Assessment of RAS-RAF-MAPK Pathway Mutation Status in Healthy Skin, Benign Nevi, and Cutaneous Melanomas: Pilot Study Using Droplet Digital PCR.International journal of molecular sciences · 2024
   Article
2. Melittin fromAntibiotics (Basel, Switzerland) · 2020
   Article
3. Antiangiogenic antibody improves melanoma detection by fluorescently labeled therapeutic antibodies.The Laryngoscope · 2016
   Article
4. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway.Targeted oncology · 2015
   Article

Corrections and comments

• Commented on by
  Constitutive expression of epidermal growth factor receptors on normal human melanocytes.2005

Authors and funding

2 authors at 1 institution in 1 country.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as